Abeona Therapeutics 2025 net income slightly misses estimates on higher SG&A costs

Abeona Therapeutics

17/03/2026 11:40

Overview

US biopharma firm's 2025 net income slightly missed analyst expectations

Income from operations missed analyst consensus, reflecting higher SG&A costs post-ZEVASKYN launch

2025 revenue reflects first ZEVASKYN commercial treatment and milestone license revenue

Outlook

Company expects ZEVASKYN launch momentum to build in first qtr 2026

Abeona expects growing ZEVASKYN treatment experience to catalyze further demand

Company expects average net revenues to normalize as payer mix expands to include commercial insurance

Result Drivers

ZEVASKYN LAUNCH - First commercial patient treatment completed in December, with launch momentum building in early 2026

LICENSE MILESTONE - License and other revenues driven by a clinical milestone reached under the October 2020 sublicense agreement with Taysha Gene Therapies

COMMERCIAL TRANSITION COSTS - SG&A expenses rose due to commercial transition after ZEVASKYN FDA approval, including personnel, stock-based compensation, and commercialization costs

Company press release: ID:nGNX858Dgd

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
Slight Miss*
$71.18 mln
$71.19 mln (5 Analysts)
FY Income From Operations
Miss
-$89.45 mln
-$78.37 mln (7 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Abeona Therapeutics Inc is $20.00, about 304% above its March 16 closing price of $4.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)